Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 2/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MPI | P34949 | 1/20 | 0.48 |
| ▸ | CDC25B | P30305 | 3/20 | 0.45 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10436098 | 0.85 | NQO2 (0.52) | NQO2ESR1ESR2KDM4EMEN1 | |
| SCHEMBL8782470 | 0.83 | NQO2 (0.59) | NQO2KDM4EMEN1ALDH1A1HPGD | |
| SCHEMBL7943832 | 0.83 | NQO2 (0.59) | NQO2KDM4EMEN1ALDH1A1HPGD | |
| SCHEMBL7265107 | 0.80 | TLR8 (0.49) | NQO2KDM4EMEN1ALDH1A1HPGD | |
| SCHEMBL2010355 | 0.80 | NQO2 (0.55) | NQO2ESR1ESR2KDM4EMEN1 | |
| SCHEMBL21585548 | 0.80 | NQO2 (0.55) | NQO2KDM4EMEN1ALDH1A1HPGD | |
| SCHEMBL8782950 | 0.80 | NQO2 (0.55) | NQO2KDM4EMEN1ALDH1A1HPGD | |
| SCHEMBL28437424 | 0.79 | TDP1 (0.62) | NQO2KDM4EMEN1ALDH1A1HPGD | |
| SCHEMBL14626630 | 0.79 | NQO2 (0.50) | NQO2KDM4EMEN1ALDH1A1HPGD | |
| SCHEMBL29120678 | 0.79 | ALOX5 (0.50) | NQO2ESR1KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-11999723-B2 | Pyrazole-containing macrophage migration inhibitory factor inhibitors | YALE UNIVERSITY (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230057076-A1 | Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors | UNIV YALE (US) | 2023-02-23 | — | — | US | disclosed |
| US-20230057076-A1 | Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors | UNIV YALE (US) | 2023-02-23 | — | — | US | disclosed |
| EP-4130000-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUND | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| US-20230026856-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SPARCBIO LLC | 2023-01-26 | — | — | US | disclosed |
| US-20190233440-A1 | Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents | PFIZER INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-20190127336-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE | ARAXES PHARMA, LLC | 2019-05-02 | — | — | US | disclosed |
| US-10246424-B2 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-04-02 | — | — | US | disclosed |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170022184-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-01-26 | — | — | US | disclosed |
| US-7514520-B2 | Process for producing phosphonitrilic acid ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20080091050-A1 | Process For Producing Phosphonitrilic Acid Ester | ASAHI KASEI CHEMICAL CORPORATION (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20070060739-A1 | Process for producing phosphonitrilic acid ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
| CN-1798753-A | Process for producing phosphonitrilic acid ester | ASAHI CHEMICAL CORP (JP) | 2006-07-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | NQO2 446/4885ESR1 4556/4885ESR2 4301/4885 |
| US-11999723-B2 | Pyrazole-containing macrophage migration inhibitory factor inhibitors | MIF, MMP12, CSF1R | NQO2 2630/4885ESR1 3975/4885ESR2 2585/4885 |
| US-20080091050-A1 | Process For Producing Phosphonitrilic Acid Ester | PHOSPHO1, GNPAT, SELENOI | NQO2 2791/4885ESR1 1669/4885ESR2 2651/4885 |
| US-10246424-B2 | Substituted quinazoline compounds and methods of use thereof | KRAS, NRAS, HRAS | NQO2 114/4885ESR1 424/4885ESR2 1612/4885 |
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | NQO2 2504/4885ESR1 1816/4885ESR2 335/4885 |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | NQO2 1702/4885ESR1 926/4885ESR2 3283/4885 |
| US-20190127336-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE | NRAS, KRAS, HRAS | NQO2 109/4885ESR1 4597/4885ESR2 3540/4885 |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | NQO2 402/4885ESR1 2203/4885ESR2 3675/4885 |
| US-20190233440-A1 | Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents | DPYD, TYMP, TOP2A | NQO2 47/4885ESR1 4586/4885ESR2 4158/4885 |
| US-20170022184-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | NQO2 147/4885ESR1 630/4885ESR2 1923/4885 |
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | KRAS, MDM2, NRAS | NQO2 2486/4885ESR1 664/4885ESR2 1465/4885 |
| US-20230026856-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | NQO2 131/4885ESR1 3543/4885ESR2 3555/4885 |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | KRAS, NRAS, HRAS | NQO2 446/4885ESR1 4556/4885ESR2 4301/4885 |
| US-20230057076-A1 | Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors | MIF, MMP12, CSF1R | NQO2 2630/4885ESR1 3975/4885ESR2 2585/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | NQO2 672/4885ESR1 1518/4885ESR2 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.